A Proposed Protocol for the Investigation of the Safety and Efficacy of the COVID-19 Vaccine for Patients with Psychosis and Pilot Safety Findings from a Chinese Psychiatrist’s Self-Experiment

Yun Sun; Chongguang Lin; Jiayue Chen; Qianchen L; Weiliang Yang; Cong Yao; Lina Wang; Ziyao Cai; Jing Ping; Ce Chen; Langlang Cheng; Jinjing Zhu; Guangdong Chen; Peiwei Shan; Chunmian Chen; Tao Fang; Hongjun Tian; Chuanjun Zhuo

ISSN: 2332-0877

Journal des maladies infectieuses et de la thérapie

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Politiques et éthique de publication

Indexé dans

Index Copernic
Google Scholar
Ouvrir la porte J
Recherche de référence
Université Hamdard
EBSCO AZ
OCLC-WorldCat
Publons
Euro Pub
ICMJE

Liens utiles

Revues en libre accès

Partager cette page

Abstrait

A Proposed Protocol for the Investigation of the Safety and Efficacy of the COVID-19 Vaccine for Patients with Psychosis and Pilot Safety Findings from a Chinese Psychiatrist?s Self-Experiment

Yun Sun, Chongguang Lin, Jiayue Chen, Qianchen L, Weiliang Yang, Cong Yao, Lina Wang, Ziyao Cai, Jing Ping, Ce Chen,Langlang Cheng, Jinjing Zhu, Guangdong Chen, Peiwei Shan, Chunmian Chen, Tao Fang, Hongjun Tian and Chuanjun Zhuo

We present a study protocol designed to test the safety and efficacy of the 2019 Coronavirus Disease (COVID-19) vaccine in
patients with major psychotic disease. A secondary objective is to investigate optional vaccination methods for these patients. In a selfexperiment,
a Chinese psychiatrist examined the safety and efficacy of the COVID-19 vaccine under clinical use of typical antipsychotic
agents and sedatives (olanzapine, duloxetine, and diazepam). For patients with extremely drug-resistant conditions, the safety of the
COVID-19 vaccine under electroconvulsive therapy was also investigated. The entire study process was recorded on high-definition
video. This clinical study protocol is, to our knowledge, the first of its kind. Our findings will shed new light on the protection of patients
with psychotic diseases from COVID-19 infection.